Ticker League

Alnylam Pharmaceuticals (ALNY) Profit Bridge

See what drove Alnylam Pharmaceuticals's net income from TTM through Q1 2025 to TTM through Q1 2026 — every line ranked by dollar impact, from revenue gains to taxes.

TTM

Revenue YoY

+82.57%

Operating Income YoY

+751.92%

Net Income YoY

+314.00%

Net Margin Δ

+2499 bps

Net income bridge for Alnylam Pharmaceuticals (ALNY) — TTM through Q1 2026 vs TTM through Q1 2025

Δ Net income: $846.92M+314.00%

Profit bridge breakdown for Alnylam Pharmaceuticals (ALNY) — TTM through Q1 2026 vs TTM through Q1 2025

  • Prior Net Income−$269.70M
  • Revenue$1.94B
  • Cost of Revenue−$490.59M
  • Operating Expenses−$580.72M
  • Other Income / Expense$74.28M
  • Income Tax−$63.54M
  • Other Items−$31.32M
  • Net Income$577.22M
Identity check: drivers reconcile to ΔNI within $0.00
Want the full P&L structure?Income Statement Waterfall

Frequently asked questions

Data & methodology

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation